Acadia Pharmaceuticals Announces Planned Year-End Retirement of Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development, Following a Distinguished Career

Acadia Pharmaceuticals announced the planned year-end retirement of Dr. Elizabeth H.Z. Thompson, Head of Research and Development, who will remain in her role until a successor is found. To ensure continuity during the Phase 2 readout of remlifanserin in Alzheimer’s disease psychosis, Acadia will retain Dr.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.